Rapamycin Delays Growth of Wnt-1 Tumors Despite Immune Suppression
Author Information
Author(s): Svirshchevskaya Elena V, Mariotti Jacopo, Wright Mollie H, Viskova Natalia Y, Telford William, Fowler Daniel H, Varticovski Lyuba
Primary Institution: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, National Cancer Institute, NIH
Hypothesis
Does Rapamycin's immune suppression affect tumor growth in Wnt-1 mammary tumors?
Conclusion
Rapamycin has a direct anti-tumor effect on Wnt-1 breast cancer while also suppressing host immune responses.
Supporting Evidence
- Rapamycin treatment significantly delayed tumor growth in both naïve and irradiated mice.
- T cell depletion and reduced cytokine secretion were observed within 7 days of therapy.
- Adoptive T cell therapy did not improve outcomes compared to Rapamycin therapy alone.
Takeaway
Rapamycin can slow down the growth of certain breast tumors, but it also weakens the immune system.
Methodology
The study used a transplantation model to examine the effects of Rapamycin on tumor growth and the immune system in mice.
Limitations
The study did not confirm that T cell immunity suppression contributes to tumor growth.
Participant Demographics
C57BL/6 mice, 6-8 weeks old.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website